Stocks and Investing
Stocks and Investing
Mon, April 29, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Aydin Huseynov Downgraded (ACRV) to Hold on, Apr 29th, 2024
Aydin Huseynov of Ladenburg Thalmann, Downgraded "Acrivon Therapeutics, Inc." (ACRV) to Hold on, Apr 29th, 2024.
Aydin has made no other calls on ACRV in the last 4 months.
There are 4 other peers that have a rating on ACRV. Out of the 4 peers that are also analyzing ACRV, 0 agree with Aydin's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Aydin
- Etzer Darout of "BMO Capital" Maintained at Buy with Increased Target to $25 on, Friday, April 26th, 2024
- Joseph Catanzaro of "Piper Sandler" Maintained at Buy with Increased Target to $30 on, Thursday, April 25th, 2024
- Silvan Tuerkcan of "JMP Securities" Maintained at Buy with Increased Target to $17 on, Thursday, April 25th, 2024
- Emily Bodnar of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $20 on, Thursday, April 25th, 2024
Contributing Sources